Switch to:
Also traded in: Germany, Mexico, Spain, UK, USA
» Details

Insider Trades

Latest Guru Trades with GIFLF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412 
Compare:OTCPK:UCBJY, NAS:BMRN, OTCPK:GMXAY, OTCPK:NVZMF, NAS:SGEN, NAS:JAZZ, NAS:ALKS, NAS:UTHR, NAS:EXEL, NAS:VRTX, NAS:IONS, NAS:ACAD, NAS:ARIA, NAS:ALNY, NAS:TECH, NAS:BLUE, NAS:RARE, OTCPK:GLPGF, NAS:CBPO, NAS:ICPT » details
Traded in other countries:G0FB.Germany, GRFPN.Mexico, GRF.P.Spain, 0RDU.UK, GRFS.USA,
Grifols SA is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. It operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials and Others.

Grifols SA Was incorporated on June 22, 1987. It is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. The Company operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials. The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The main plasma products it manufactures are IVIG, Factor VIII, A1PI and albumin. It also manufactures intramuscular immunoglobulins, ATIII, Factor IX and plasma thromboplastin component, or PTC. The Diagnostic division focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. The Company concentrates its Diagnostic business in immunohematology and hemostasis product lines. The Diagnostic division's main customers are blood donation centers, clinical analysis laboratories and hospital immunohematology services. The Raw Material division provides raw materials for its intravenous therapy products like plastic and glass bottles, which the company purchases from various European suppliers. The Hospital division manufactures and installs products used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids, which are sold almost exclusively in Spain and Portugal. It also includes products that the company does not manufacture. The Company operates in Latin America, in countries such as Mexico, Colombia, Argentina, Chile and Brazil. It sells Bioscience, Diagnostic and Hospital products to hospitals and clinics, GPOs, governments and other distributors globally. The Company's operations are subject to government authorities in the United States, at the federal, state and local level, and in other countries in which it operates.

Ratios

vs
industry
vs
history
PE Ratio 28.51
GIFLF's PE Ratio is ranked lower than
51% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 26.13 vs. GIFLF: 28.51 )
Ranked among companies with meaningful PE Ratio only.
GIFLF' s PE Ratio Range Over the Past 10 Years
Min: 22.16  Med: 33.45 Max: 96.2
Current: 28.51
22.16
96.2
Forward PE Ratio 17.99
GIFLF's Forward PE Ratio is ranked higher than
51% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. GIFLF: 17.99 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 28.51
GIFLF's PE Ratio without NRI is ranked higher than
51% of the 185 Companies
in the Global Biotechnology industry.

( Industry Median: 26.61 vs. GIFLF: 28.51 )
Ranked among companies with meaningful PE Ratio without NRI only.
GIFLF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 22.08  Med: 32.31 Max: 97.1
Current: 28.51
22.08
97.1
Price-to-Owner-Earnings 40.31
GIFLF's Price-to-Owner-Earnings is ranked lower than
63% of the 128 Companies
in the Global Biotechnology industry.

( Industry Median: 25.00 vs. GIFLF: 40.31 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GIFLF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.07  Med: 32.75 Max: 47.23
Current: 40.31
18.07
47.23
PB Ratio 4.36
GIFLF's PB Ratio is ranked lower than
52% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 3.85 vs. GIFLF: 4.36 )
Ranked among companies with meaningful PB Ratio only.
GIFLF' s PB Ratio Range Over the Past 10 Years
Min: 2.32  Med: 4.18 Max: 6.76
Current: 4.36
2.32
6.76
PS Ratio 3.84
GIFLF's PS Ratio is ranked higher than
71% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.96 vs. GIFLF: 3.84 )
Ranked among companies with meaningful PS Ratio only.
GIFLF' s PS Ratio Range Over the Past 10 Years
Min: 1.9  Med: 3.5 Max: 6.38
Current: 3.84
1.9
6.38
Price-to-Free-Cash-Flow 36.93
GIFLF's Price-to-Free-Cash-Flow is ranked lower than
61% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 23.86 vs. GIFLF: 36.93 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GIFLF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 15.58  Med: 30.03 Max: 117.79
Current: 36.93
15.58
117.79
Price-to-Operating-Cash-Flow 22.51
GIFLF's Price-to-Operating-Cash-Flow is ranked higher than
52% of the 158 Companies
in the Global Biotechnology industry.

( Industry Median: 22.05 vs. GIFLF: 22.51 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GIFLF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 11.01  Med: 18.46 Max: 154
Current: 22.51
11.01
154
EV-to-EBIT 20.70
GIFLF's EV-to-EBIT is ranked lower than
52% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 18.89 vs. GIFLF: 20.70 )
Ranked among companies with meaningful EV-to-EBIT only.
GIFLF' s EV-to-EBIT Range Over the Past 10 Years
Min: -98  Med: 19.5 Max: 38.7
Current: 20.7
-98
38.7
EV-to-EBITDA 16.98
GIFLF's EV-to-EBITDA is ranked higher than
52% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 16.23 vs. GIFLF: 16.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
GIFLF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -28.1  Med: 15.9 Max: 29.4
Current: 16.98
-28.1
29.4
PEG Ratio 0.89
GIFLF's PEG Ratio is ranked higher than
73% of the 89 Companies
in the Global Biotechnology industry.

( Industry Median: 1.81 vs. GIFLF: 0.89 )
Ranked among companies with meaningful PEG Ratio only.
GIFLF' s PEG Ratio Range Over the Past 10 Years
Min: 0.6  Med: 0.9 Max: 1.15
Current: 0.89
0.6
1.15
Current Ratio 3.19
GIFLF's Current Ratio is ranked lower than
54% of the 585 Companies
in the Global Biotechnology industry.

( Industry Median: 3.45 vs. GIFLF: 3.19 )
Ranked among companies with meaningful Current Ratio only.
GIFLF' s Current Ratio Range Over the Past 10 Years
Min: 2.19  Med: 2.99 Max: 3.31
Current: 3.19
2.19
3.31
Quick Ratio 1.52
GIFLF's Quick Ratio is ranked lower than
71% of the 583 Companies
in the Global Biotechnology industry.

( Industry Median: 3.24 vs. GIFLF: 1.52 )
Ranked among companies with meaningful Quick Ratio only.
GIFLF' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.52 Max: 1.88
Current: 1.52
1.15
1.88
Days Inventory 256.26
GIFLF's Days Inventory is ranked lower than
81% of the 314 Companies
in the Global Biotechnology industry.

( Industry Median: 129.42 vs. GIFLF: 256.26 )
Ranked among companies with meaningful Days Inventory only.
GIFLF' s Days Inventory Range Over the Past 10 Years
Min: 235.92  Med: 293.73 Max: 763.71
Current: 256.26
235.92
763.71
Days Sales Outstanding 34.65
GIFLF's Days Sales Outstanding is ranked higher than
74% of the 405 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. GIFLF: 34.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
GIFLF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.61  Med: 82.66 Max: 97.36
Current: 34.65
33.61
97.36
Days Payable 68.51
GIFLF's Days Payable is ranked higher than
58% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 56.51 vs. GIFLF: 68.51 )
Ranked among companies with meaningful Days Payable only.
GIFLF' s Days Payable Range Over the Past 10 Years
Min: 64.56  Med: 105.84 Max: 256.52
Current: 68.51
64.56
256.52

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 1.58
GIFLF's Dividend Yield % is ranked higher than
66% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 1.45 vs. GIFLF: 1.58 )
Ranked among companies with meaningful Dividend Yield % only.
GIFLF' s Dividend Yield % Range Over the Past 10 Years
Min: 0.38  Med: 1.22 Max: 1.79
Current: 1.58
0.38
1.79
Dividend Payout Ratio 0.39
GIFLF's Dividend Payout Ratio is ranked higher than
81% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 0.35 vs. GIFLF: 0.39 )
Ranked among companies with meaningful Dividend Payout Ratio only.
GIFLF' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.2  Med: 0.3 Max: 0.56
Current: 0.39
0.2
0.56
Forward Dividend Yield % 2.67
GIFLF's Forward Dividend Yield % is ranked higher than
73% of the 226 Companies
in the Global Biotechnology industry.

( Industry Median: 1.34 vs. GIFLF: 2.67 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.58
GIFLF's 5-Year Yield-on-Cost % is ranked higher than
65% of the 291 Companies
in the Global Biotechnology industry.

( Industry Median: 1.59 vs. GIFLF: 1.58 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
GIFLF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.38  Med: 1.22 Max: 1.79
Current: 1.58
0.38
1.79
3-Year Average Share Buyback Ratio -1.50
GIFLF's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 503 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. GIFLF: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GIFLF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -46.1  Med: -8.4 Max: -0.4
Current: -1.5
-46.1
-0.4

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.04
GIFLF's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
67% of the 156 Companies
in the Global Biotechnology industry.

( Industry Median: 3.03 vs. GIFLF: 2.04 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GIFLF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.74  Med: 2.56 Max: 12.38
Current: 2.04
1.74
12.38
Price-to-Median-PS-Value 1.10
GIFLF's Price-to-Median-PS-Value is ranked lower than
52% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 0.99 vs. GIFLF: 1.10 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GIFLF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 1 Max: 1.55
Current: 1.1
0.59
1.55
Price-to-Peter-Lynch-Fair-Value 1.22
GIFLF's Price-to-Peter-Lynch-Fair-Value is ranked higher than
59% of the 66 Companies
in the Global Biotechnology industry.

( Industry Median: 1.55 vs. GIFLF: 1.22 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GIFLF' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.95  Med: 1.04 Max: 1.22
Current: 1.22
0.95
1.22
Earnings Yield (Greenblatt) % 4.81
GIFLF's Earnings Yield (Greenblatt) % is ranked higher than
84% of the 639 Companies
in the Global Biotechnology industry.

( Industry Median: -6.50 vs. GIFLF: 4.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GIFLF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.6  Med: 5.1 Max: 7.9
Current: 4.81
2.6
7.9
Forward Rate of Return (Yacktman) % 25.84
GIFLF's Forward Rate of Return (Yacktman) % is ranked higher than
66% of the 119 Companies
in the Global Biotechnology industry.

( Industry Median: 15.08 vs. GIFLF: 25.84 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GIFLF' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 25.8  Med: 30.5 Max: 42
Current: 25.84
25.8
42

More Statistics

Revenue (TTM) (Mil) $4,463
EPS (TTM) $ 0.88
Beta0.82
Short Percentage of Float0.00%
52-Week Range $17.80 - 22.75
Shares Outstanding (Mil)682.82

Analyst Estimate

Dec16 Dec17
Revenue (Mil $) 4,219 4,417
EPS ($) 0.94 1.12
EPS without NRI ($) 0.94 1.12
EPS Growth Rate
(Future 3Y To 5Y Estimate)
7.20%
Dividends per Share ($) 0.33 0.41
» More Articles for GIFLF

Headlines

Articles On GuruFocus.com
John Paulson's Largest 3rd Quarter Trades Dec 01 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
Gold-Focused Guru John Paulson Reports First Quarter Holdings May 22 2014 
Is Grifols Being Overlooked? Mar 19 2014 
John Paulson's Top Five Holdings Nov 20 2013 
John Paulson's Top Five Holdings Sep 12 2013 
Baron Funds Comments on Grifols SA Aug 30 2012 
Friday Value Overview Aug 19 2011 

More From Other Websites
Grifols SA breached its 50 day moving average in a Bullish Manner : GIFLF-US : December 26, 2016 Dec 26 2016
Grifols SA : A good buy now? Relative to peers, maybe. Dec 20 2016
Hologic (HOLX) to Divest Blood Screening Business to Grifols Dec 19 2016
Grifols to buy Hologic's stake in blood screening JV for $1.85 billion Dec 14 2016
Virgin America Inc (VA): Is It Right For Your Portfolio? Dec 09 2016
Ligand Pharmaceuticals Inc. (LGND): Hedge Fund Sentiment Unchanged Dec 05 2016
What Explains the Huge Jump in Louisiana-Pacific Corporation (LPX)’s Hedge Fund Ownership? Nov 25 2016
Zika Blood Screening Test From Hologic, Grifols Gets FDA Nod Jun 20 2016
Hologic And Grifols Get FDA Approval For Procleix Zika Virus Assay Jun 20 2016
Analyzing IBB’s Moving Averages Jun 16 2016
Grifols Maintains Its Dividend Payout at 40% Jun 01 2016
Is Grifols SA, Barcelona (GRFS) A Good Stock To Buy? Dec 02 2015
Here is What Hedge Funds Think About Textron Inc. (TXT) Dec 01 2015
Should You Buy Goldcorp Inc. (USA) (GG)? Nov 27 2015
Is MGM Resorts International (MGM) A Good Stock To Buy? Nov 23 2015
Billionaire John Paulson Standing Pat With His Top Small-Cap Picks May 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK